All In Biotech

Drug Trial Radar · NCT06980480

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

183

Planned (sponsor's estimate)

Start

Jan 14, 2026

Primary completion

Sep 11, 2028

Study completion Sep 11, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part of Takeda
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy. Participants will be randomly assigned to one of two groups: 1. Primary infection prevention group: They will receive IGI, 10% for 12 months. 2. Secondary infection prevention group: They will only receive IGI, 10% if they develop a serious infection during the 12 months study period. During the study, participants will visit their study clinic 15 times (for 4-week dosing interval) or 19 times (for 3-week dosing interval) and their total participation duration will be up to 14 months (including screening period approximately 8 weeks).

Conditions

  • Multiple Myeloma
  • Secondary Immunodeficiency

Interventions

  • IGI, 10%Biological

    IGI, 10% IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time To the First Serious InfectionTime frame: Up to 12 months

Locations

68 sites in 17 countries. Site status is shown where the registry gives one.

  • Infirmary Health - Diagnostic & Medical Clinic (DMC)

    Mobile, Alabama · Recruiting

  • Chao Family Comprehensive Cancer Center UCI

    Orange, California · Recruiting

  • University of Kansas

    Westwood, Kansas · Recruiting

  • University of Maryland | Greenebaum Cancer Center

    Baltimore, Maryland · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • New York Oncology Hematology

    Albany, New York · Recruiting

  • St Vincents Hospital Melbourne

    Melbourne, Australia · Recruiting

  • St George Private Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Townsville Hospital

    Douglas, Queensland, Australia · Recruiting

  • Greenslopes Private Hospital

    Greenslopes, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Freemasons Hospital, Epworth Health

    East Melbourne, Victoria, Australia · Recruiting

  • Western Health - Sunshine Hospital

    St Albans, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • A O Krankenhaus der Elisabethinen

    Linz, Austria · Recruiting

  • Universitaetsklinikum St. Poelten

    Sankt Pölten, Austria · Recruiting

  • Krankenhaus der Barmherzigen Schwestern Wien

    Vienna, Austria · Recruiting

  • Sao Jose do Rio Preto Regional Faculty of Medicine FoundationSao Jose do Rio Preto Regional Faculty of Medicine Foundation

    Porto Alegre, Brazil · Recruiting

  • Instituto Oncoclínicas de Ensino

    Rio de Janeiro, Brazil · Recruiting

  • Instituto D'Or de Pesquisa e Ensino

    Salvador, Brazil · Recruiting

  • Instituto D'Or de Pesquisa e Ensino - Sao Paulo

    São Paulo, Brazil · Recruiting

  • Centro de Hematologia e Oncologia (CHO)

    Joinville, Santa Catarina, Brazil · Recruiting

  • Cancer Care Manitoba

    Winnipeg, Manitoba, Canada · Recruiting

  • Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada · Recruiting

  • Fakultni Nemocnice Ostrava (FNO) - Neurologicke klinika

    Ostrava, Czechia · Recruiting

  • Aalborg Hospital

    Aalborg, Denmark · Recruiting

  • Aarhus Universitetshospital

    Aarhus, Denmark · Recruiting

  • Copenhagen University Hospital

    Copenhagen, Denmark · Recruiting

  • Odense Universitetshospital

    Odense, Denmark · Recruiting

  • Alexandra General Hospital of Athens

    Athens, Greece · Recruiting

  • University General Hospital of Ioannina

    Ioannina, Greece · Recruiting

  • University of Debrecen DEOEC

    Debrecen, Hungary · Recruiting

  • Somogy Megyei Kaposi Mor Oktato Korhaz

    Kaposvár, Hungary · Recruiting

  • Markusovszky Egyetemi Oktatokorhaz

    Szombathely, Hungary · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Azienda Ospedaliero Universitaria Policlinico G. Rodolico San Marco

    Catania, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    Pavia, Italy · Recruiting

  • Azienda Sanitaria Locale di Pescara Ospedale Civile Dello Spirito Santo

    Pescara, Italy · Recruiting

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.